Powers Pauline S, Bruty Heidi
College of Medicine, University of South Florida, 3515 East Fletcher Avenue, Tampa, FL 33613, USA.
Child Adolesc Psychiatr Clin N Am. 2009 Jan;18(1):175-87. doi: 10.1016/j.chc.2008.07.009.
Anorexia nervosa and bulimia nervosa are significant mental health problems in the adolescent population; however, there are no medications approved by the FDA for the treatment of adolescents with either of these disorders. Many medications are used off label for both the symptoms of eating disorders and their co-morbid conditions, particularly SSRIs and atypical anti-psychotics. The dosing, side effect profile, and long term effects of these medications in children and adolescents is unclear. Binge eating disorder, night eating syndrome, and sleep-related eating disorder often are associated with over-weight in adolescents. There are various pharmacological approaches to the treatment of obesity in the adolescent population some of which have FDA approval. In the article the authors discuss pharmacological approaches to guide the treatment of eating disorders and obesity in the pediatric population, including risks of treatment, monitoring of potential side effects, and recent outcomes in the literature.
神经性厌食症和神经性贪食症是青少年群体中严重的心理健康问题;然而,美国食品药品监督管理局(FDA)并未批准任何药物用于治疗患有这两种疾病的青少年。许多药物被用于治疗饮食失调及其共病状况的症状,特别是选择性5-羟色胺再摄取抑制剂(SSRI)和非典型抗精神病药物。这些药物在儿童和青少年中的剂量、副作用情况以及长期影响尚不清楚。暴饮暴食症、夜间饮食综合征和与睡眠相关的饮食失调通常与青少年超重有关。在青少年群体中,有多种治疗肥胖的药物方法,其中一些已获得FDA批准。在本文中,作者讨论了指导儿科人群饮食失调和肥胖治疗的药物方法,包括治疗风险、潜在副作用的监测以及文献中的近期研究结果。